PDF herunterladen
Semin Neurol 2007; 27(5): 453-459
DOI: 10.1055/s-2007-991125
© Thieme Medical Publishers

Pregnancy and Epilepsy

Cynthia L. Harden1
  • 1Comprehensive Epilepsy Center, Department of Neurology, Weill Cornell Medical College, New York, New York
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. Oktober 2007 (online)

    Lizenzen und Reprints

ABSTRACT

The management of women with epilepsy who are planning a pregnancy or who are currently pregnant remains one of the most perplexing and engaging clinical issues for neurologists. A refinement of surveillance methods, along with a greater understanding of teratogenesis, has provided us with better information regarding specific antiepileptic drug (AED)-associated teratogenic risk than in the past. A recent finding from multiple worldwide AED pregnancy registries is an increased teratogenic risk with valproate compared with the other AEDs, supporting previous retrospective reports. Valproate use and independently having more than five convulsive seizures during pregnancy are associated with a risk of decreased verbal intelligence quotient (IQ) in the offspring. The European pregnancy register confirms that most women who are seizure-free early in pregnancy have an excellent chance of maintaining seizure freedom throughout pregnancy. The management of AEDs during pregnancy continues to be explored, and considerations for dosing and therapeutic monitoring are discussed herein. The metabolism of both lamotrigine and oxcarbazepine is induced during pregnancy, and careful clinical monitoring and frequent level assessment are emerging as important for these AEDs.

KEYWORDS

Pregnancy - epilepsy - seizure

REFERENCES

  • 1 Practice parameter: a guideline for discontinuing antiepileptic drugs in seizure-free patients (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 1996;  47 600-602
    PubMedGoogle Scholar
  • 2 Practice parameter: management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 1998;  51 944-948
    PubMedGoogle Scholar
  • 3 Loughnan P M, Gold H, Vance J C. Phenytoin teratogenicity in man.  Lancet. 1973;  1 70-72
    PubMedGoogle Scholar
  • 4 Holmes L B, Harvey E A, Coull B A et al.. The teratogenicity of anticonvulsant drugs.  N Engl J Med. 2001;  344 1132-1138
    CrossrefPubMedGoogle Scholar
  • 5 Wyszynski D F, Nambisan M, Surve T, Alsdorf R M, Smith C R, Holmes L B. Increased rate of major malformations in offspring exposed to valproate during pregnancy.  Neurology. 2005;  64 961-965
    CrossrefPubMedGoogle Scholar
  • 6 Holmes L B, Wyszynski D F, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience.  Arch Neurol. 2004;  61 673-678
    CrossrefPubMedGoogle Scholar
  • 7 Vajda F J, Eadie M J. Maternal valproate dosage and foetal malformations.  Acta Neurol Scand. 2005;  112 137-143
    CrossrefPubMedGoogle Scholar
  • 8 Morrow J, Russell A, Guthrie E et al.. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.  J Neurol Neurosurg Psychiatry. 2005;  77 193-198
    PubMedGoogle Scholar
  • 9 Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study.  Acta Paediatr. 2004;  93 174-176
    CrossrefPubMedGoogle Scholar
  • 10 Artama M, Auvinen A, Raudaskoski T, Isojärvi I, Isojärvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring.  Neurology. 2005;  64 1874-1878
    CrossrefPubMedGoogle Scholar
  • 11 Correa-Villasenor A, Satten G A, Rolka H, Langlois P, Devine O. Random error and undercounting in birth defects surveillance data: implications for inference.  Birth Defects Res A Clin Mol Teratol. 2003;  67 610-616
    CrossrefPubMedGoogle Scholar
  • 12 Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy.  Neurology. 2005;  64 955-960
    CrossrefPubMedGoogle Scholar
  • 13 Holmes L B, Wyszynski D F, Baldwin E J, Haebecker E, Glassman L H, Smith C R. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy [abstract].  Birth Defects Res Part A Clin Mol Teratol. 2006;  76 318
    PubMedGoogle Scholar
  • 14 Hunt S, Craig J, Russell A et al.. Levetiracetam in pregnancy: Preliminary experience from the UK Epilepsy and Pregnancy Register.  Neurology. 2006;  67 1876-1879
    CrossrefPubMedGoogle Scholar
  • 15 Reinisch J M, Sanders S A, Mortensen E L, Rubin D B. In utero exposure to phenobarbital and intelligence deficits in adult men.  JAMA. 1995;  274 1518-1525
    CrossrefPubMedGoogle Scholar
  • 16 Vinten J, Adab N, Kini U, Gorry J, Gregg J, Baker G A. Neuropsychological effects of exposure to anticonvulsant medication in utero.  Neurology. 2005;  64 949-954
    CrossrefPubMedGoogle Scholar
  • 17 Gaily E, Kantola-Sorsa E, Hiilesmaa V et al.. Normal intelligence in children with prenatal exposure to carbamazepine.  Neurology. 2004;  62 28-32
    CrossrefPubMedGoogle Scholar
  • 18 Holmes L B, Coull B A, Dorfman J, Rosenberger P B. The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs.  J Pediatr. 2005;  146 118-122
    PubMedGoogle Scholar
  • 19 Minkoff H, Schaffer R M, Delke I, Grunebaum A N. Diagnosis of intracranial hemorrhage in utero after a maternal seizure.  Obstet Gynecol. 1985;  65 22S-24S
    PubMedGoogle Scholar
  • 20 Teramo K, Hiilesmaa V, Bardy A, Saarikoski S. Fetal heart rate during a maternal grand mal epileptic seizure.  J Perinat Med. 1979;  7 3-6
    PubMedGoogle Scholar
  • 21 Hiilesmaa V K, Bardy A, Teramo K. Obstetric outcome in women with epilepsy.  Am J Obstet Gynecol. 1985;  152 499-504
    PubMedGoogle Scholar
  • 22 Zahn C. Neurologic care of pregnant women with epilepsy.  Epilepsia. 1998;  39(suppl 8) S26-S31
    CrossrefPubMedGoogle Scholar
  • 23 Nulman I, Laslo D, Koren G. Treatment of epilepsy in pregnancy.  Drugs. 1999;  57 535-544
    CrossrefPubMedGoogle Scholar
  • 24 The EURAP Study Group . Seizure control and treatment in pregnancy: observations from the EURAP Epilepsy Pregnancy Registry.  Neurology. 2006;  66 354-360
    CrossrefPubMedGoogle Scholar
  • 25 Meador K J, Baker G A, Finnell R H et al.. NEAD Study Group. In utero antiepileptic drug exposure: fetal death and malformations.  Neurology. 2006;  67 407-412
    CrossrefPubMedGoogle Scholar
  • 26 Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin.  Epilepsia. 1994;  35 122-130
    CrossrefPubMedGoogle Scholar
  • 27 Kalviainen R, Tomson T. Optimizing treatment of epilepsy during pregnancy.  Neurology. 2006;  67(suppl 4) S59-S63
    PubMedGoogle Scholar
  • 28 Yerby M S, Friel P N, McCormick K. Antiepileptic drug disposition during pregnancy.  Neurology. 1992;  42(suppl 5) 12-16
    PubMedGoogle Scholar
  • 29 Battino D, Binelli S, Bossi L et al.. Changes in primidone/phenobarbital ration during pregnancy and the puerperium.  Clin Pharmacokinet. 1984;  9 252-269
    PubMedGoogle Scholar
  • 30 Tran T A, Leppik I E, Blesi K, Sathanandan S T, Remmel R. Lamotrigine clearance during pregnancy.  Neurology. 2002;  59 251-255
    PubMedGoogle Scholar
  • 31 Pennell P B, Newport D J, Stowe Z N, Helmers S L, Montgomery Q J, Henry T R. The impact of pregnancy and childbirth on the metabolism of lamotrigine.  Neurology. 2004;  62 292-295
    PubMedGoogle Scholar
  • 32 Mazzucchelli I, Onat F Y, Ozkara C et al.. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.  Epilepsia. 2006;  47 504-509
    CrossrefPubMedGoogle Scholar
  • 33 Christensen J, Savers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy.  Neurology. 2006;  67 1497-1499
    CrossrefPubMedGoogle Scholar
  • 34 Beck-Mannagetta G, Janz D. Syndrome-related genetics in generalized epilepsy.  Epilepsy Res Suppl. 1991;  4 105-111
    PubMedGoogle Scholar
  • 35 Ottman R, Annegers J F, Hauser W A, Kurland L T. Higher risk of seizures in offspring of mothers than of fathers with epilepsy.  Am J Hum Genet. 1988;  43 257-264
    PubMedGoogle Scholar
  • 36 Angelsen N K, Vik T, Jacobsen G, Bakketeig L S. Breast feeding and cognitive development at age 1 and 5 years.  Arch Dis Child. 2001;  85 183-188
    CrossrefPubMedGoogle Scholar
  • 37 Pennell P B. Antiepileptic drug pharmacokinetics during pregnancy and lactation.  Neurology. 2003;  61(suppl 2) S35-S42
    PubMedGoogle Scholar
  • 38 Liporace J, Kao A, D'Abreu A. Concerns regarding lamotrigine and breast-feeding.  Epilepsy Behav. 2004;  5 102-105
    CrossrefPubMedGoogle Scholar
  • 39 Johannessen S I, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation.  Epilepsia. 2005;  46 775-777
    CrossrefPubMedGoogle Scholar
  • 40 Ohman I, Vitols S, Luef G, Soderfeldt B, Tomson T. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations.  Epilepsia. 2002;  43 1157-1160
    CrossrefPubMedGoogle Scholar
  • 41 Kaaja E, Kaaja R, Matila R, Hiilesmaa V. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate.  Neurology. 2002;  58 549-553
    PubMedGoogle Scholar
  • 42 Czeizel A E, Dobó M, Vargha P. Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities.  Birth Defects Res A Clin Mol Teratol. 2004;  70 853-861
    PubMedGoogle Scholar

Cynthia L HardenM.D. 

Professor of Neurology, Comprehensive Epilepsy Center, Department of Neurology, Weill Cornell Medical College

525 East 68th Street, Room K-615, New York, NY 10021

eMail: clharden@med.cornell.edu